Table 1

Characteristics of the randomized controlled trials included in the meta-analysis

Trials (first author, year)NMoInsulin regimenDesign analog (shot/day)Age(years)Male (%)OHAs< /≤ 7%NaïveStart HbA1cTitrationStatisticsQuality scoreInsulin dose (units/kg)
Malone, 2004 (23)1054BiphasicCO Lispro25 (×2)55.362.38.7%0.62
BasalGlargine55.362.3MetYes8.7%NoNo ITT30.57
Malone, 2005 (24)974BiphasicCO Lispro25 (×2)59.3428.5%0.42
BasalGlargine59.342MetNo8.5%NoITT20.28
Raskin, 2005 (25)2336BiphasicP Aspart30 (×2)52.6539.7%0.82
BasalGlargine52.357Met + Pio<Yes9.8%YesITT20.55
Kann, 2006 (26)2556BiphasicP Aspart30 (×2)61.553.99.2%0.39
BasalGlargine6148.8Glimepiride<Mix8.9%NoITT20.39
Jacober, 2006 (27)604BiphasicCO Lispro50 (×2) + Lispro2554.956.79.2%0.35
BasalGlargine54.956.7Met/Su/TzdYes9.2%NoNo ITT20.28
Kazda, 2006 (28)1076BiphasicP Lispro50 (×3)59.4548.1%0.59
BasalGlargine59.454No<Yes8.1%NoITT20.43
Kazda, 2006 (28)1066BiphasicP Lispro50 (×3)59.4548.1%0.59
PrandialLispro (×3)59.454No<Yes8.2%NoITT20.50
Kazda, 2006 (28)1056PrandialP Lispro (×3)59.4548.2%0.50
BasalGlargine59.454No<Yes8.1%NoITT20.43
Holman, 2007 (29)46912BiphasicP Aspart30 (×2)61.764.18.6%0.53
BasalDetemir61.764.1Met + SuYes8.4%YesITT40.49
Holman, 2007 (29)47412BiphasicP Aspart30 (×2)61.764.18.6%0.53
PrandialAspart (×3)61.764.1Met + SuYes8.6%YesITT40.61
Holman, 2007 (29)47212PrandialP Aspart (×3)61.764.18.6%0.61
BasalDetemir61.764.1Met + SuYes8.4%YesITT40.49
Robbins, 2007 (30)3156BiphasicP Lispro50 (×3)57.749.87.8%0.7
BasalGlargine57.749.8MetNo7.8%YesITT40.6
Bretzel, 2008 (31)41810.5PrandialP Lispro (×3)59.7598.7%0.53
BasalGlargine6052Met, SuYes8.7%YesITT40.50
Hirao, 2008 (32)1176BiphasicP Aspart30 (×2)58.558.710.6%
PrandialLispro (×3)57.961.2No<Yes10.6%NoNo ITT2
Rosenstock, 2008 (33)3746BiphasicP Lispro50 (×3)55.4538.8%1.2
Basal-bolusLispro (×3) + Glargine5452No Su<No8.9%YesComplete31.4
Liebl, 2009 (34)7154BiphasicP Aspart30 (×2)61.7638.4%0.62
Basal-bolusAspart (×3) + Detemir60.363NoNo8.5%YesITT20.88
Buse, 2009 (35)20916BiphasicP Lispro25 (×2)5752.89.1%0.47
BasalGlargine5752.8Met/Su/TzdYes9.0%YesITT40.4
Raz, 2009 (36)111531BasalP Glargine6063.38.3%0.52
PrandialLispro (×3)6063.3No<No8.4%YesITT40.60
Strojek, 2009 (37)4806BasalP Glargine56.141.2Met +8.5%0.29
BiphasicAspart30 (×1)55.946.8Glimep<Yes8.5%YesITT20.32
Holman, 2009 (38)69836BiphasicP Aspart30 (×2) + Aspart61.764.18.6%0.78
Basal-bolusAspart (×3) + Detemir61.764.1NoNo8.6%YesITT40.97
  • CO, crossover group; P, parallel group; OHAs, oral hypoglycemic agents; Met, metformin; Su, sulfonylurea; Tzd, thiazolidinedione; ITT, intention to treat.